The House Ways and Means Oversight Subcommittee today held a hearing focused on the Centers for Medicare & Medicaid Services’ efforts to use data to identify Medicare Part D beneficiaries who are at risk of misusing opioids. The hearing also examined the tools CMS has available to limit overprescribing. Witnesses were Kimberly Brandt, CMS principal deputy administrator for operations; Gary Cantrell, deputy inspector general for investigations at the Department of Health and Human Services’ Office of Inspector General; and Elizabeth Curda, director of health care at the Government Accountability Office. In addition, the Senate Committee on Homeland Security and Governmental Affairs today examined Medicaid and the opioid epidemic. Witnesses were Sam Adolphsen, senior fellow at the Foundation for Government Accountability; Otto Schalk, prosecuting attorney for Harrison County, IN; Emmanuel Tyndall, inspector general of Tennessee; David Hyman, M.D., of the Georgetown University Law Center; and Andrew Kolodny, M.D., co-director of opioid policy research at Brandeis University.

Related News Articles

Headline
The Health Resources and Services Administration yesterday awarded 120 organizations, including hospitals, $200,000 each to develop community partnerships and…
Headline
Laws that allow pharmacists to dispense the opioid antidote naloxone without a physician’s prescription are associated with a sharp reduction in fatal opioid-…
Headline
The White House Office of National Drug Control Policy seeks by 2022 to reduce drug overdose deaths and youth illicit drug use by 15 percent and opioid…
Perspective
Investing in our country’s health infrastructure is the right move to make.
Headline
The AHA yesterday announced support for the Opioid Workforce Act of 2019, bipartisan legislation to reduce the nation’s shortage of opioid treatment providers…
Headline
The National Academy of Medicine Action Collaborative on Countering the U.S. Opioid Epidemic, of which the AHA is a sponsor, held a two-day meeting this week…